Supernus Pharmaceuticals, Inc. SUPN 深 沪
等待开盘 08-10 09:30:00 美东时间
47.64
+0.880
+1.88%
华盛通- 最 高48.40
- 今 开47.00
- 成交量 68.89万股
- 最 低 42.625
- 昨 收 46.76
- 总市值 254.46万
- 52周最高 59.68
- 市盈率 静 48.47
- 换手率 1289.69%
- 52周最低 41.783
- 委 比 -6.13%
- 总股本 5.34万
- 历史最高 61.25
- 量 比 0.49
- 振 幅 12.35%
- 历史最低 1.10
- 每 手 1
- 风险率 3.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Supernus Pharmaceuticals to acquire Sage Therapeutics for up to $795 million, gaining ZURZUVAE for postpartum depression, enhancing its neuropsychiatric portfolio and expected to drive growth starting in 2026.
2025-06-16 11:00
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
<p>Supernus Pharmaceuticals partners with Jay Glazer and his wife Rosie in a new video series exploring ADHD's impact on relationships and Jay's use of Qelbree for symptom management. The series aims to raise awareness and encourage open discussions about ADHD treatment.</p>
2025-05-29 12:30
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
Supernus Pharmaceuticals received Paragraph IV Notice Letters about ANDAs for viloxazine extended-release capsules. The company is reviewing the details and plans to enforce its intellectual property rights for Qelbree. Six U.S. patents are listed in the FDA's Orange Book, expiring in 2029, 2033, and 2035.
2025-05-28 20:05
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
Supernus Pharmaceuticals CEO Jack A. Khattar will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on June 4, 2025. Investors may arrange meetings with company management or watch the live webcast at the provided links. The company focuses on developing CNS disease treatments.
2025-05-28 20:05
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million.
2024-09-12 02:38
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-11 21:08
Piper Sandler Downgrades Supernus Pharmaceuticals to Neutral, Lowers Price Target to $36
Piper Sandler analyst David Amsellem downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Overweight to Neutral and lowers the price target from $41 to $36.
2024-09-11 18:41
Sector Update: Health Care Stocks Edge Higher Premarket Monday
09:24 AM EDT, 08/19/2024 (MT Newswires) -- Health care stocks were edging higher premarket Monday as the iShares Biotechnology ETF (IBB) was 0.3% higher and the Health Care Select Sector SPDR Fund (XLV) was up 0.2% recently. Liquidia (LQDA) shares fell by over 38% after saying it has received tentat...
2024-08-19 21:24
Supernus Pharmaceuticals Says US FDA Accepts NDA Resubmission for Potential Parkinson's Related Treatment Device
08:15 AM EDT, 08/19/2024 (MT Newswires) -- Supernus Pharmaceuticals (SUPN) said Monday that the US Food and Drug Administration had accepted its resubmission of a new drug application for its apomorphine infusion device, which is intended for continuous treatment of motor fluctuations in Parkinson's...
2024-08-19 20:15
